Detailed company information
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q3Released: Aug 07, 2026
Earnings Transcript for 2026 - Q2Released: May 05, 2026
Earnings Transcript for 2026 - Q1Released: Feb 05, 2026
Earnings Transcript for 2025 - Q4Released: Nov 25, 2025
Earnings Transcript for 2025 - Q3Released: Aug 08, 2025
Earnings Transcript for 2025 - Q2Released: May 09, 2025
Earnings Transcript for 2025 - Q1Released: Feb 06, 2025
Earnings Transcript for 2024 - Q4Released: Nov 26, 2024
Earnings Transcript for 2024 - Q3Released: Aug 09, 2024
Earnings Transcript for 2024 - Q2Released: May 09, 2024
Earnings Transcript for 2024 - Q1Released: Feb 09, 2024
Earnings Transcript for 2023 - Q4Released: Nov 21, 2023
Earnings Transcript for 2023 - Q3Released: Aug 13, 2023
Earnings Transcript for 2023 - Q2Released: May 12, 2023
Earnings Transcript for 2023 - Q1Released: Feb 14, 2023
Earnings Transcript for 2022 - Q4Released: Dec 20, 2022
Earnings Transcript for 2022 - Q3Released: Aug 15, 2022
Earnings Transcript for 2022 - Q2Released: May 13, 2022
ANGO AngioDynamics, Inc.
Dafinchi
